MX2011013661A - Composiciones y metodos para el tratamiento de esclerosis multiple. - Google Patents

Composiciones y metodos para el tratamiento de esclerosis multiple.

Info

Publication number
MX2011013661A
MX2011013661A MX2011013661A MX2011013661A MX2011013661A MX 2011013661 A MX2011013661 A MX 2011013661A MX 2011013661 A MX2011013661 A MX 2011013661A MX 2011013661 A MX2011013661 A MX 2011013661A MX 2011013661 A MX2011013661 A MX 2011013661A
Authority
MX
Mexico
Prior art keywords
treatment
compositions
methods
multiple sclerosis
concerned
Prior art date
Application number
MX2011013661A
Other languages
English (en)
Inventor
Frank B Gelder
Gillian Alison Webster
Original Assignee
Innate Immunotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Immunotherapeutics Ltd filed Critical Innate Immunotherapeutics Ltd
Publication of MX2011013661A publication Critical patent/MX2011013661A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Photographic Developing Apparatuses (AREA)

Abstract

La presente invención se refiere a nuevas composiciones y métodos para el tratamiento de Esclerosis Múltiple (MS) y en particular a composiciones inmunoestimuladoras que comprenden micropartículas de muramil dipéptido en el tratamiento de MS.
MX2011013661A 2009-06-16 2010-06-16 Composiciones y metodos para el tratamiento de esclerosis multiple. MX2011013661A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis
PCT/NZ2010/000112 WO2010147484A1 (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
MX2011013661A true MX2011013661A (es) 2012-05-22

Family

ID=42646236

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013661A MX2011013661A (es) 2009-06-16 2010-06-16 Composiciones y metodos para el tratamiento de esclerosis multiple.

Country Status (21)

Country Link
US (1) US8389479B2 (es)
EP (1) EP2442832B1 (es)
JP (1) JP5646617B2 (es)
CN (1) CN102458476B (es)
AU (1) AU2010260585B2 (es)
BR (1) BRPI1009606A2 (es)
CA (1) CA2688766C (es)
CY (1) CY1115714T1 (es)
DK (1) DK2442832T3 (es)
ES (1) ES2521565T3 (es)
HK (1) HK1167101A1 (es)
HR (1) HRP20141035T1 (es)
IL (1) IL216993A (es)
IN (1) IN2012DN00167A (es)
MX (1) MX2011013661A (es)
NZ (1) NZ577731A (es)
PL (1) PL2442832T3 (es)
PT (1) PT2442832E (es)
SI (1) SI2442832T1 (es)
SM (1) SMT201400165B (es)
WO (1) WO2010147484A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101983063A (zh) * 2008-04-01 2011-03-02 伊耐特医疗技术有限公司 抗感染剂及其用途
WO2012061074A1 (en) 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
AU2016202146A1 (en) * 2015-10-06 2017-04-20 Innate Immunotherapeutics Limited Compositions and methods for protection and/or repair of the nervous system
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
WO2019218079A1 (en) * 2018-05-18 2019-11-21 Universite Laval Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
WO2020010221A1 (en) * 2018-07-03 2020-01-09 University Of Florida Research Foundation, Inc. Microparticle systems and their use for the treatment of multiple sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502315A (ja) * 1996-10-10 2001-02-20 プローブ・インターナショナル ウイルス感染を処置するための組成物および方法
US20080193440A1 (en) * 2004-07-01 2008-08-14 Kobenhavns Universitet Method For Multiple Sclerosis Treatment and Prophylaxis By Treatment of Leptospira Infection
US8603978B2 (en) * 2006-12-01 2013-12-10 The United States of America, as represented by the Secretary, Department of Health and Humand Services Use of muramyl dipeptide (MDP) for treating inflammation
JP2008251608A (ja) 2007-03-29 2008-10-16 Casio Comput Co Ltd 半導体装置およびその製造方法
WO2008150181A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treating anthrax exposure associated conditions
WO2008150182A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treatment of anthrax

Also Published As

Publication number Publication date
US20100317589A1 (en) 2010-12-16
SMT201400165B (it) 2015-01-15
JP5646617B2 (ja) 2014-12-24
SI2442832T1 (sl) 2014-12-31
EP2442832B1 (en) 2014-08-06
WO2010147484A8 (en) 2012-07-19
AU2010260585A1 (en) 2012-01-19
CN102458476B (zh) 2014-08-20
NZ577731A (en) 2010-08-27
EP2442832A1 (en) 2012-04-25
JP2012530132A (ja) 2012-11-29
CY1115714T1 (el) 2017-01-25
CN102458476A (zh) 2012-05-16
DK2442832T3 (da) 2014-11-10
ES2521565T3 (es) 2014-11-12
HRP20141035T1 (hr) 2014-12-19
PL2442832T3 (pl) 2015-01-30
BRPI1009606A2 (pt) 2016-10-11
PT2442832E (pt) 2014-11-11
WO2010147484A1 (en) 2010-12-23
IN2012DN00167A (es) 2015-04-17
IL216993A0 (en) 2012-02-29
HK1167101A1 (en) 2013-02-01
CA2688766C (en) 2015-06-30
CA2688766A1 (en) 2010-12-16
US8389479B2 (en) 2013-03-05
EP2442832A4 (en) 2013-07-03
IL216993A (en) 2016-03-31
AU2010260585A8 (en) 2012-06-14
AU2010260585B2 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
IN2012DN00167A (es)
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
IL246293A0 (en) New preparations and methods for the treatment of vaccine-related diseases
PH12014500053A1 (en) Proteasome inhibitors
EP2464724A4 (en) COMPOSITIONS AND METHODS FOR IMPLANTATION OF TREATED ADIPOSE TISSUE AND TREATED ADIPOSE TISSUE PRODUCTS
IN2012DN03883A (es)
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
MX2011009690A (es) Métodos y composiciones para trastornos relacionados con la proliferación celurar.
JO2860B1 (en) Phenylendazolyl compounds
IN2012DN00971A (es)
MX2011013577A (es) Composiciones y metodos para tratar esclerosis lateral amiotrofica.
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
MX361011B (es) Inhibidores de amida hidrolasa de ácido graso.
EP2566485A4 (en) IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
EP2445873A4 (en) PROTEASE INHIBITORS, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USE
MY161460A (en) Elastomeric dental floss
MX2011010046A (es) Derivados de diaminopteridina.
MX2012012509A (es) Tapentadol para usarse en el tratamiento del sindrome del intestino irritable.
TN2011000041A1 (en) Compositions and methods for antibodies targeting complement protein c5
MY180594A (en) Proteasome inhibitors
GEP20146006B (en) Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3- dimethyl-butyramide

Legal Events

Date Code Title Description
FG Grant or registration